clr3 Antibody

What is CRLF3 and why is it important in research?

CRLF3, also known as Cytokine Receptor-Like Factor 3, is a protein that functions within the cytokine receptor family. It plays a significant role in the negative regulation of cell cycle progression, making it an important target for cell proliferation studies. CRLF3 is also known by several alternative designations including CREME9, CRLM9, CYTOR4, and P48, which researchers should be aware of when reviewing literature . Understanding CRLF3's function is crucial for investigating cellular signaling pathways, particularly those involved in cell division control. Research into this protein contributes to broader understanding of cellular homeostasis mechanisms and potential dysregulation in disease states.

What types of CRLF3 antibodies are available for research applications?

Research-grade CRLF3 antibodies are predominantly available as monoclonal antibodies, with mouse monoclonal antibodies being particularly common. These antibodies are generated using recombinant full-length human CRLF3 protein as the immunogen, ensuring recognition of native protein conformations . Monoclonal antibodies offer advantages in terms of specificity and reproducibility compared to polyclonal alternatives. When selecting a CRLF3 antibody, researchers should consider the clonal designation (e.g., OTI2H3) and validation data specific to their intended application. The antibody isotype (commonly IgG) determines downstream detection strategies and potential functional applications.

What applications are CRLF3 antibodies validated for?

CRLF3 antibodies have been validated for multiple research applications including Western blotting (WB) and immunohistochemistry with paraffin-embedded tissues (IHC-P) . For Western blotting, CRLF3 antibodies typically detect a band at approximately 50 kDa, which corresponds to the predicted molecular weight of the protein. In immunohistochemistry applications, these antibodies have been successfully used to detect CRLF3 in human tissues such as spleen. Researchers should note that application-specific optimizations may be necessary, including adjustments to antibody dilution (typically starting at 1:500 for both WB and IHC-P), incubation times, and detection systems based on experimental requirements.

How should researchers optimize Western blotting protocols for CRLF3 detection?

Optimization of Western blotting for CRLF3 detection requires careful consideration of several parameters. Based on published protocols, researchers should begin with a 1:500 dilution of primary antibody and adjust based on signal strength . For cell line experiments, loading approximately 35 μg of total protein extract has yielded successful detection of CRLF3. NCI-H460 human lung cancer cells have been validated as a positive control source. The expected band size of 50 kDa serves as a critical reference point, though post-translational modifications may cause slight variations in apparent molecular weight. Membrane blocking conditions, antibody incubation times, and washing stringency should be systematically optimized to maximize signal-to-noise ratio. Unlike some transmembrane proteins that require special extraction methods, standard RIPA or NP-40 based lysis buffers are generally sufficient for CRLF3 extraction.

How can researchers validate the specificity of their CRLF3 antibody?

Validating CRLF3 antibody specificity requires a multi-pronged approach. First, researchers should confirm the predicted molecular weight (50 kDa) in Western blot applications across multiple cell lines with known CRLF3 expression levels . Second, peptide competition assays, where the antibody is pre-incubated with excess purified CRLF3 protein or immunogenic peptide, should abolish specific signals. Third, genetic approaches using CRLF3 knockdown (siRNA or shRNA) or knockout (CRISPR-Cas9) followed by antibody staining provides strong validation. Fourth, correlation between protein detection and mRNA expression data across tissues or cell lines adds another layer of validation. Finally, cross-reactivity testing against closely related cytokine receptor family members ensures the antibody doesn't recognize similar epitopes in other proteins.

How can CRLF3 antibodies be employed in multi-parameter flow cytometry?

Implementing CRLF3 antibodies in multi-parameter flow cytometry requires attention to several methodological details. Researchers should first determine whether CRLF3 detection requires cell permeabilization, as its predicted localization may include both membrane and intracellular components. For intracellular detection, methanol or paraformaldehyde-based fixation followed by saponin or Triton X-100 permeabilization protocols are recommended. Antibody titration is essential to determine optimal staining concentrations, typically starting with manufacturer recommendations and adjusting based on signal-to-noise ratio. When designing multi-parameter panels, spectral overlap must be considered, selecting fluorophores for CRLF3 detection that minimize overlap with other markers of interest. Compensation controls and fluorescence-minus-one (FMO) controls are critical for accurate analysis. For clinical samples, additional blocking steps to reduce non-specific binding to Fc receptors may be necessary.

What approaches can be used to study CRLF3 expression in different cellular compartments?

Studying subcellular localization of CRLF3 requires specialized methodologies. Confocal microscopy combined with compartment-specific markers provides high-resolution visualization of CRLF3 distribution. Co-staining with markers for plasma membrane (Na+/K+ ATPase), cytoplasm (tubulin), nucleus (DAPI), and various organelles helps define precise localization patterns. For biochemical validation, subcellular fractionation followed by Western blotting with CRLF3 antibodies can quantify distribution across different cellular compartments. Proximity ligation assays (PLA) can detect interactions between CRLF3 and other proteins within specific compartments at nanometer resolution. Live-cell imaging using fluorescently-tagged CRLF3 antibody fragments (Fabs) can track dynamic changes in localization, though care must be taken to ensure antibody internalization doesn't affect normal protein trafficking.

How can researchers effectively use CRLF3 antibodies in co-immunoprecipitation studies?

For successful co-immunoprecipitation (co-IP) studies with CRLF3 antibodies, researchers should optimize several parameters. First, cell lysis conditions must preserve protein-protein interactions while efficiently extracting CRLF3 and its binding partners. Gentle, non-ionic detergents (0.5-1% NP-40 or Triton X-100) are typically preferred over stringent ionic detergents. Second, antibody immobilization method significantly impacts efficiency—direct conjugation to resin may reduce heavy chain contamination in subsequent Western blot analysis compared to protein A/G-based capture. Third, the antibody-to-lysate ratio requires optimization, typically starting with 2-5 μg antibody per 500 μg total protein. Fourth, washing stringency balances between preserving specific interactions and reducing background. Finally, elution conditions (native vs. denaturing) should be selected based on downstream applications. Controls should include isotype-matched irrelevant antibodies and, ideally, CRLF3-depleted lysates.

What strategies can address inconsistent results when using CRLF3 antibodies across different experimental systems?

Addressing inconsistent CRLF3 antibody results requires systematic troubleshooting. First, researchers should verify target expression in their experimental system through RT-qPCR or other methods independent of antibody detection. Second, epitope accessibility may vary between applications—antibodies recognizing native conformations may perform differently in applications requiring denatured proteins . Third, cell-type specific post-translational modifications may affect antibody recognition. Fourth, lot-to-lot variability of antibodies necessitates validation of each new lot. Fifth, protocol standardization across laboratories should include detailed documentation of critical parameters (buffer compositions, incubation times/temperatures, detection systems). When multiple antibodies are available, using antibodies targeting different epitopes can provide orthogonal validation. Additionally, researchers should consider that the antibody might recognize different isoforms of CRLF3 with varying efficiency.

How should researchers interpret differences in CRLF3 detection between immunohistochemistry and Western blotting?

Interpreting discrepancies between immunohistochemistry and Western blotting results for CRLF3 requires understanding the fundamental differences between these techniques. Western blotting detects denatured proteins separated by size, while immunohistochemistry visualizes proteins in their native tissue context . Several factors may explain discrepancies: (1) Epitope accessibility—formalin fixation can mask epitopes that are readily accessible in denatured samples; (2) Protein aggregation or complex formation may alter detection in one format but not the other; (3) Cross-reactivity profiles may differ between applications; (4) Sensitivity differences—Western blotting can detect lower abundance proteins through signal accumulation; (5) Sample preparation—phosphatase or protease activity during tissue processing may modify epitopes. Researchers should validate findings through orthogonal methods such as RNA expression analysis, multiple antibodies targeting different epitopes, or genetic manipulation of CRLF3 expression.

What are the challenges in developing highly specific antibodies against transmembrane proteins like cytokine receptors?

Developing specific antibodies against transmembrane proteins presents unique challenges. First, these proteins often exist within families sharing high sequence homology, increasing the risk of cross-reactivity . For instance, cytokine receptors like CRLF3 share structural features with related family members, complicating specific recognition. Second, the transmembrane nature limits accessible epitopes primarily to extracellular and intracellular domains. Third, native conformation is critical—antibodies raised against linear peptides may fail to recognize the three-dimensional structure of the protein in cellular contexts. Fourth, the relatively low expression of many transmembrane proteins complicates immunization strategies. Techniques to overcome these challenges include using conformational epitopes through intact cell immunization, recombinant expression of protein fragments in native conformation, and lipoparticle technology that presents membrane proteins in their natural lipid environment .

How have phage display technologies improved antibody development for complex targets like CRLF3?

Phage display technology has revolutionized antibody development for challenging targets like CRLF3. This approach offers several advantages: (1) It bypasses traditional hybridoma limitations, allowing selection under precisely controlled conditions; (2) It enables screening of extremely large antibody libraries (>10^10 different clones) for rare high-affinity binders; (3) It permits direct selection against native protein conformations using stable cells overexpressing the target or embedded lipoparticles ; (4) It facilitates antibody engineering through affinity maturation, humanization, or format switching. The technique involves displaying antibody fragments (commonly scFv) on bacteriophage surfaces, followed by multiple rounds of binding and enrichment against the target protein. This iterative process results in progressively higher affinity antibodies. For transmembrane proteins like cytokine receptors, phage display has enabled isolation of conformation-specific antibodies with sub-nanomolar affinities that recognize native epitopes .

What role do antibody-dependent cellular cytotoxicity (ADCC) properties play in research applications of CRLF3 antibodies?

Antibody-dependent cellular cytotoxicity (ADCC) properties significantly impact research applications beyond standard detection methods. ADCC occurs when antibodies bind target cells and engage Fc receptors (particularly FcγRIIIa/CD16a) on effector cells like natural killer cells, triggering cytotoxicity . For research applications, ADCC activity enables functional studies of target depletion in complex cellular systems. When designing such experiments, researchers must consider several factors: antibody isotype (human IgG1 typically mediates strongest ADCC), Fc region glycosylation pattern, target density on cells, and effector cell source. ADCC assays require specialized methodologies including: (1) Quantifying target expression levels, (2) Preparing appropriate effector cells (primary NK cells or engineered reporter cell lines), (3) Establishing accurate target:effector ratios, and (4) Selecting appropriate readouts (cytotoxicity markers, cytokine release, or reporter signals). These properties also inform potential therapeutic applications, as ADCC contributes to the mechanism of action for many therapeutic antibodies.